Skip to content Skip to navigation

Announcement:

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Announcement:

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma

Flagship Pioneering
  • Generative Biology®
  • The Generate Platform™
  • Pipeline
  • About Us
  • Careers
  • Media Center
  • Investors
  • LinkedIn
  • X
  • YouTube
Presentations & Publications

ERS 2025: ePoster

09.28.2025
Download as PDF
  • Generative Biology®
  • The Generate Platform™
  • Pipeline
  • About Us
  • Careers
  • Media Center
  • Investors
Now we can.

Contact Us


Generate:Biomedicines
101 South Street, Suite 900
Somerville, MA 02143
United States

© 2026 Generate:Biomedicines
  • LinkedIn
  • X
  • YouTube
Privacy Policy Terms of Use Cookie Settings